comprehensive -WSS

comprehensive

author：leisure time 2025-09-27 22:05:53 - browse：6753

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Listen: Racing for gene therapy & a pioneering approval

hotspot

WSS

Meta looks to target Twitter with a rival app called Threads

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Listen: PBM conflicts, RSV vaccines, & the future of flu season

The pain doctors face in trying to build their families

Did the public have the right to know Arthur Ashe had AIDS?

RaDonda Vaught case: a double standard for nurses, physicians

entertainment

comprehensive

focus

Hollywood unions extend contract negotiations for actors

Cancer drug shortages' outsize impact on ovarian cancer patients

Heart attack and stroke risk calculators need revising

Trump cancels press conference intended to dispute Georgia election interference charges

Moonlake's readout produced a cash windfall. Risks remain

Hilary expected to bring catastrophic, life

After affirmative action ruling, medical educators look to 'holistic review'

Congress must give Medicare recipients genetic counseling access

As demand for Covid shots wanes, Moderna seeks its next success

Cancer drug shortages' outsize impact on ovarian cancer patients

Wikipedia

Living with Hashimoto's and celiac disease, and med school, too

Hilary expected to bring catastrophic, life

Beware the threat of staffing cuts at the CDC

Hilary may become 1st tropical storm to make landfall in California in 84 years

Liz Cheney makes 1st public comment since Trump's election interference indictments

Evacuations in place as 3 wildfires burn in eastern Washington state

hotspot

leisure time

leisure time

Wikipedia